PI3-kinase inhibition: a target for drug development?

The phosphoinositide 3-kinases (PI3-kinases) are a ubiquitously expressed enzyme family that, through the generation of phospholipid second messengers, play a key role in the regulation of many cellular processes. These include motility, proliferation and survival, and carbohydrate metabolism. Members of the PI3-kinase family and related kinases, their mechanism of activation and the cellular events that they influence are described in this review. As knowledge of their involvement in disease processes increases, the PI3-kinases appear to be an increasingly attractive target for drug development, particularly in the fields of cancer and other proliferative diseases, and in the treatment of inflammatory and immunological conditions. Evidence of the functional specialization of PI3-kinase isoforms suggests that selective inhibition with acceptable toxicity might be possible.

[1]  P. Hawkins,et al.  Cell biology: Moving in mysterious ways , 2000, Nature.

[2]  A. Klippel,et al.  Activation of Phosphatidylinositol 3-Kinase Is Sufficient for Cell Cycle Entry and Promotes Cellular Changes Characteristic of Oncogenic Transformation , 1998, Molecular and Cellular Biology.

[3]  Y. Yazaki,et al.  p85α Gene Generates Three Isoforms of Regulatory Subunit for Phosphatidylinositol 3-Kinase (PI 3-Kinase), p50α, p55α, and p85α, with Different PI 3-Kinase Activity Elevating Responses to Insulin* , 1997, The Journal of Biological Chemistry.

[4]  M. Zerial,et al.  Phosphatidylinositol-3-OH kinases are Rab5 effectors , 1999, Nature Cell Biology.

[5]  C. Mitchell,et al.  Increased levels of phosphatidylinositol 3‐kinase activity in colorectal tumors , 1998, Cancer.

[6]  P. Vogt,et al.  The Catalytic Subunit of Phosphoinositide 3-Kinase: Requirements for Oncogenicity* , 2000, The Journal of Biological Chemistry.

[7]  G. Cooper,et al.  Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. , 1995, Science.

[8]  L. Pirola,et al.  Structure and function of phosphoinositide 3-kinases. , 1998, Biochimica et biophysica acta.

[9]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[10]  Y. Shiloh,et al.  ATM: A mediator of multiple responses to genotoxic stress , 1999, Oncogene.

[11]  Domenico Coppola,et al.  Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer , 2000, Oncogene.

[12]  L. Pfeffer,et al.  NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase , 1999, Nature.

[13]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors , 2000 .

[14]  Chen-Yang Shen,et al.  PIK3CA as an oncogene in cervical cancer , 2000, Oncogene.

[15]  L. Pirola,et al.  Bifurcation of lipid and protein kinase signals of PI3Kgamma to the protein kinases PKB and MAPK. , 1998, Science.

[16]  Andrius Kazlauskas,et al.  PDGF induces an early and a late wave of PI 3-kinase activity, and only the late wave is required for progression through G1 , 1999, Current Biology.

[17]  M. Zvelebil,et al.  Class II Phosphoinositide 3-Kinases Are Downstream Targets of Activated Polypeptide Growth Factor Receptors , 2000, Molecular and Cellular Biology.

[18]  M. Waterfield,et al.  A family of phosphoinositide 3-kinases in Drosophila identifies a new mediator of signal transduction , 1995, Current Biology.

[19]  B. Calabretta,et al.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI‐3k/Akt‐dependent pathway , 1997, The EMBO journal.

[20]  R. Nussbaum,et al.  Proliferative Defect and Embryonic Lethality in Mice Homozygous for a Deletion in the p110α Subunit of Phosphoinositide 3-Kinase* , 1999, The Journal of Biological Chemistry.

[21]  M. Waterfield,et al.  Signaling by distinct classes of phosphoinositide 3-kinases. , 1999, Experimental cell research.

[22]  M. Waterfield,et al.  Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages , 1999, Nature Cell Biology.

[23]  J. Cheng,et al.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.

[24]  M. Koegl,et al.  The phosphatidylinositol 3-kinase alpha is required for DNA synthesis induced by some, but not all, growth factors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Downward,et al.  Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3‐kinase , 1998, The EMBO journal.

[26]  D. Olive,et al.  PI 3-kinase: a pivotal pathway in T-cell activation? , 1996, Immunology today.

[27]  S. Jackson,et al.  The DNA-dependent protein kinase , 1999 .

[28]  Y. Matsuzawa,et al.  Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3–kinase , 1999, Nature Genetics.

[29]  Y. Yazaki,et al.  Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase. , 1999, Science.

[30]  M. Waterfield,et al.  A comparison of demethoxyviridin and wortmannin as inhibitors of phosphatidylinositol 3‐kinase , 1994, FEBS letters.

[31]  R. K. McEwen,et al.  The stress-activated phosphatidylinositol 3-phosphate 5-kinase Fab1p is essential for vacuole function in S. cerevisiae , 1998, Current Biology.

[32]  Asim Khwaja,et al.  Matrix adhesion and Ras transformation both activate a phosphoinositide 3‐OH kinase and protein kinase B/Akt cellular survival pathway , 1997, The EMBO journal.

[33]  C. Heldin,et al.  The PI 3-kinase isoforms p110(alpha) and p110(beta) have differential roles in PDGF- and insulin-mediated signaling. , 2000, Journal of cell science.

[34]  A. Kazlauskas,et al.  Phospholipase C-γ1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal , 1993, Cell.

[35]  B. Vanhaesebroeck,et al.  The PI3K-PDK1 connection: more than just a road to PKB. , 2000, The Biochemical journal.

[36]  J. Dodge,et al.  Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. , 1994, Cancer research.

[37]  G. Evan,et al.  Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB , 1997, Nature.

[38]  A. Klip,et al.  Actin filaments participate in the relocalization of phosphatidylinositol3-kinase to glucose transporter-containing compartments and in the stimulation of glucose uptake in 3T3-L1 adipocytes. , 1998, The Biochemical journal.

[39]  G. Panayotou,et al.  Phospholipid-binding protein domains. , 1998, Biochimica et biophysica acta.

[40]  L. Schriml,et al.  Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. , 1999, Journal of the National Cancer Institute.

[41]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[42]  S. Emr,et al.  Fab1p Is Essential for PtdIns(3)P 5-Kinase Activity and the Maintenance of Vacuolar Size and Membrane Homeostasis , 1998, The Journal of cell biology.

[43]  J. Flores,et al.  Increased phosphoinositide 3‐kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  G. Thomas,et al.  Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. , 1999, Current opinion in genetics & development.

[45]  Sally J. Leevers.  All Creatures Great and Small , 1999, Science.

[46]  M. Waterfield,et al.  The study of phosphoinositide 3-kinase function. , 1996, Cancer surveys.

[47]  S. Schreiber,et al.  Overexpression of a kinase‐inactive ATR protein causes sensitivity to DNA‐damaging agents and defects in cell cycle checkpoints , 1998, The EMBO journal.

[48]  W. Liu,et al.  Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines* , 1999, The Journal of Biological Chemistry.

[49]  P. Kang,et al.  The conserved phosphoinositide 3‐kinase pathway determines heart size in mice , 2000, The EMBO journal.

[50]  Christian Ried,et al.  Structural insights into phosphoinositide 3-kinase catalysis and signalling , 1999, Nature.

[51]  F. Alt,et al.  Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. , 1999, Science.

[52]  Joseph Schlessinger,et al.  A Novel Positive Feedback Loop Mediated by the Docking Protein Gab1 and Phosphatidylinositol 3-Kinase in Epidermal Growth Factor Receptor Signaling , 2000, Molecular and Cellular Biology.

[53]  K. Siddle,et al.  Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. , 1998, The Biochemical journal.

[54]  M. Zvelebil,et al.  Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction , 1996, Molecular and cellular biology.

[55]  J. Downward,et al.  A Function for Phosphatidylinositol 3-Kinase β (p85α-p110β) in Fibroblasts during Mitogenesis: Requirement for Insulin- and Lysophosphatidic Acid-Mediated Signal Transduction , 1998, Molecular and Cellular Biology.

[56]  J. Dodge,et al.  Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. , 1996, Journal of medicinal chemistry.

[57]  Pier Paolo Pandolfi,et al.  The Multiple Roles of PTEN in Tumor Suppression , 2000, Cell.